Exact Mass: 529.2758838000001
Exact Mass Matches: 529.2758838000001
Found 500 metabolites which its exact mass value is equals to given mass value 529.2758838000001,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Glycochenodeoxycholate 7-sulfate
Glycochenodeoxycholate 7-sulfate is a bile acid derivative that plays several important roles in biology. Its primary functions include: Bile Acid Conjugation: It is a component of bile, which is synthesized in the liver and plays a crucial role in the digestion and absorption of dietary fats. The glyco moiety (sugar component) and sulfate group enhance its solubility and stability, facilitating its role in bile formation. Lipid Solubilization: In the small intestine, Glycochenodeoxycholate 7-sulfate aids in the emulsification of dietary fats. This process breaks down large fat droplets into smaller ones, increasing the surface area for action by lipase, an enzyme that breaks down triglycerides into absorbable fatty acids and monoglycerides. Cholesterol Homeostasis: Bile acids, including Glycochenodeoxycholate 7-sulfate, are involved in the regulation of cholesterol homeostasis. They facilitate the excretion of cholesterol from the body and also play a role in the enterohepatic circulation of bile acids, which recycles bile acids and helps maintain their levels. Hormonal Regulation: Bile acids, including conjugated forms like Glycochenodeoxycholate 7-sulfate, act as signaling molecules that interact with various nuclear and membrane receptors, influencing processes such as glucose and lipid metabolism, inflammation, and energy homeostasis. Detoxification: The sulfate group in Glycochenodeoxycholate 7-sulfate is involved in the detoxification of certain xenobiotics (foreign substances), aiding in their elimination from the body.
Malformin
C23H39N5O5S2 (529.2392484000001)
Malformin is produced by Aspergillus niger. It is isolated from mould damaged ric
N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]-Glycine
N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]-Glycine is an acyl glycine and a bile acid-glycine conjugate. It is a secondary bile acid produced by the action of enzymes existing in the microbial flora of the colonic environment. In hepatocytes, both primary and secondary bile acids undergo amino acid conjugation at the C-24 carboxylic acid on the side chain, and almost all bile acids in the bile duct therefore exist in a glycine conjugated form (PMID: 16949895). Technically this compound is a sulfate conjugate of glycoursodeoxycholic acid.
Glycochenodeoxycholate-3-sulfate
Glycochenodeoxycholate-3-sulfate is a bile salt formed in the liver from chenodeoxycholate and glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is a cholagogue and choleretic. [HMDB] Glycochenodeoxycholate-3-sulfate is a bile salt formed in the liver from chenodeoxycholate and glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is a cholagogue and choleretic. D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
LysoPE(0:0/22:4(7Z,10Z,13Z,16Z))
LysoPE(0:0/22:4(7Z,10Z,13Z,16Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/22:4(7Z,10Z,13Z,16Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0)
LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
(5Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine
(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Gcdcs
Haloperidol decanoate
C31H41ClFNO3 (529.2758838000001)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist
Pegnivacogin
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent
(2R)-2-Acetyl-1-[(2S)-2-[acetyl-[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carboxylic acid
N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]-Glycine
2-{(4S,5S,5aS,9aS)-4-Methoxy-6,6,9a-trimethyl-5-[(2E,4E,6E)-2,4,6-octatrienoyloxy]-1-oxo-1,3,4,5,5a,6,7,8,9,9a-decahydro-2H-benzo[E]isoindol-2-yl}pentanedioic acid
(Z)-6-[(2R,5R,8R,11R,12S)-8-(4-hydroxybenzyl)-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-11-yl]hex-4-enamide|azumamide B
4-O-(alpha-L-arabinopyranosyl) nervogenic acid lindelofidine ester|nervosine I
(1S,4S,7R,10S,13S)-7,10-di(butan-2-yl)-4-propan-2-yl-15,16-dithia-3,6,9,12,18-pentazabicyclo[11.4.2]nonadecane-2,5,8,11,19-pentone
C23H39N5O5S2 (529.2392484000001)
C29H39NO8_2-{(4S,5S,5aS,9aS)-4-Methoxy-6,6,9a-trimethyl-5-[(2E,4E,6E)-2,4,6-octatrienoyloxy]-1-oxo-1,3,4,5,5a,6,7,8,9,9a-decahydro-2H-benzo[e]isoindol-2-yl}pentanedioic acid
C29H39NO8_2-(4-Hydroxy-6-methoxy-1-oxo-5-{[(2E,6Z)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]oxy}-1,3-dihydro-2H-isoindol-2-yl)pentanedioic acid
2-[(4S,5S,5aS,9aS)-4-methoxy-6,6,9a-trimethyl-5-[(2E,4E,6E)-octa-2,4,6-trienoyl]oxy-1-oxo-4,5,5a,7,8,9-hexahydro-3H-benzo[e]isoindol-2-yl]pentanedioic acid
Glyco 3a-sulfate-7a-OH-5b-cholanic acid
BA-145-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-145-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-145-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-145-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-145-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
Glyco 3a-sulfate-7b-OH-5b-cholanic acid
BA-146-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-146-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-146-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-146-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-146-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
N-[(3a,5b,12a)-12-Hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]glycine
BA-147-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-147-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-147-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-147-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-147-30. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
(1S,4S,7R,10S,13S)-7,10-di(butan-2-yl)-4-propan-2-yl-15,16-dithia-3,6,9,12,18-pentazabicyclo[11.4.2]nonadecane-2,5,8,11,19-pentone [IIN-based: Match]
C23H39N5O5S2 (529.2392484000001)
(1S,4S,7R,10S,13S)-7,10-di(butan-2-yl)-4-propan-2-yl-15,16-dithia-3,6,9,12,18-pentazabicyclo[11.4.2]nonadecane-2,5,8,11,19-pentone [IIN-based on: CCMSLIB00000848487]
C23H39N5O5S2 (529.2392484000001)
Ala Phe His Arg
Ala Phe Arg His
Ala His Phe Arg
Ala His Arg Phe
Ala Gln Arg Arg
C20H39N11O6 (529.3084633999999)
Ala Arg Phe His
Ala Arg His Phe
Ala Arg Gln Arg
C20H39N11O6 (529.3084633999999)
Ala Arg Arg Gln
C20H39N11O6 (529.3084633999999)
Asp His Lys Met
Asp His Met Lys
Asp Ile Pro Trp
Asp Ile Trp Pro
Asp Lys His Met
Asp Lys Met His
Asp Leu Pro Trp
Asp Leu Trp Pro
Asp Met His Lys
Asp Met Lys His
Asp Pro Ile Trp
Asp Pro Leu Trp
Asp Pro Trp Ile
Asp Pro Trp Leu
Asp Trp Ile Pro
Asp Trp Leu Pro
Asp Trp Pro Ile
Asp Trp Pro Leu
Glu Glu Pro Arg
C21H35N7O9 (529.2496140000001)
Glu Glu Arg Pro
C21H35N7O9 (529.2496140000001)
Glu Pro Glu Arg
C21H35N7O9 (529.2496140000001)
Glu Pro Arg Glu
C21H35N7O9 (529.2496140000001)
Glu Pro Val Trp
Glu Pro Trp Val
Glu Arg Glu Pro
C21H35N7O9 (529.2496140000001)
Glu Arg Pro Glu
C21H35N7O9 (529.2496140000001)
Glu Val Pro Trp
Glu Val Trp Pro
Glu Trp Pro Val
Glu Trp Val Pro
Phe Ala His Arg
Phe Ala Arg His
Phe His Ala Arg
Phe His Ile Asn
C25H35N7O6 (529.2648690000001)
Phe His Lys Val
Phe His Leu Asn
C25H35N7O6 (529.2648690000001)
Phe His Asn Ile
C25H35N7O6 (529.2648690000001)
Phe His Asn Leu
C25H35N7O6 (529.2648690000001)
Phe His Gln Val
C25H35N7O6 (529.2648690000001)
Phe His Arg Ala
Phe His Val Lys
Phe His Val Gln
C25H35N7O6 (529.2648690000001)
Phe Ile His Asn
C25H35N7O6 (529.2648690000001)
Phe Ile Asn His
C25H35N7O6 (529.2648690000001)
Phe Lys His Val
Phe Lys Val His
Phe Leu His Asn
C25H35N7O6 (529.2648690000001)
Phe Leu Asn His
C25H35N7O6 (529.2648690000001)
Phe Asn His Ile
C25H35N7O6 (529.2648690000001)
Phe Asn His Leu
C25H35N7O6 (529.2648690000001)
Phe Asn Ile His
C25H35N7O6 (529.2648690000001)
Phe Asn Leu His
C25H35N7O6 (529.2648690000001)
Phe Gln His Val
C25H35N7O6 (529.2648690000001)
Phe Gln Val His
C25H35N7O6 (529.2648690000001)
Phe Arg Ala His
Phe Arg His Ala
Phe Val His Lys
Phe Val His Gln
C25H35N7O6 (529.2648690000001)
Phe Val Lys His
Phe Val Gln His
C25H35N7O6 (529.2648690000001)
Gly Lys Tyr Tyr
Gly Tyr Lys Tyr
Gly Tyr Tyr Lys
His Ala Phe Arg
His Ala Arg Phe
His Asp Lys Met
His Asp Met Lys
His Phe Ala Arg
His Phe Ile Asn
C25H35N7O6 (529.2648690000001)
His Phe Lys Val
His Phe Leu Asn
C25H35N7O6 (529.2648690000001)
His Phe Asn Ile
C25H35N7O6 (529.2648690000001)
His Phe Asn Leu
C25H35N7O6 (529.2648690000001)
His Phe Gln Val
C25H35N7O6 (529.2648690000001)
His Phe Arg Ala
His Phe Val Lys
His Phe Val Gln
C25H35N7O6 (529.2648690000001)
His Ile Phe Asn
C25H35N7O6 (529.2648690000001)
His Ile Asn Phe
C25H35N7O6 (529.2648690000001)
His Lys Asp Met
His Lys Phe Val
His Lys Met Asp
His Lys Val Phe
His Leu Phe Asn
C25H35N7O6 (529.2648690000001)
His Leu Asn Phe
C25H35N7O6 (529.2648690000001)
His Met Arg Ser
His Met Ser Arg
His Asn Phe Ile
C25H35N7O6 (529.2648690000001)
His Asn Phe Leu
C25H35N7O6 (529.2648690000001)
His Asn Ile Phe
C25H35N7O6 (529.2648690000001)
His Asn Leu Phe
C25H35N7O6 (529.2648690000001)
His Gln Phe Val
C25H35N7O6 (529.2648690000001)
His Gln Val Phe
C25H35N7O6 (529.2648690000001)
His Arg Ala Phe
His Arg Phe Ala
His Arg Met Ser
His Arg Ser Met
His Ser Met Arg
His Ser Arg Met
His Val Phe Lys
His Val Phe Gln
C25H35N7O6 (529.2648690000001)
His Val Lys Phe
His Val Gln Phe
C25H35N7O6 (529.2648690000001)
Ile Asp Pro Trp
Ile Asp Trp Pro
Ile Phe His Asn
C25H35N7O6 (529.2648690000001)
Ile Phe Asn His
C25H35N7O6 (529.2648690000001)
Ile His Phe Asn
C25H35N7O6 (529.2648690000001)
Ile His Asn Phe
C25H35N7O6 (529.2648690000001)
Ile Asn Phe His
C25H35N7O6 (529.2648690000001)
Ile Asn His Phe
C25H35N7O6 (529.2648690000001)
Ile Asn Gln Arg
Ile Asn Arg Gln
Ile Pro Asp Trp
Ile Pro Trp Asp
Ile Gln Asn Arg
Ile Gln Arg Asn
Ile Arg Asn Gln
Ile Arg Gln Asn
Ile Trp Asp Pro
Ile Trp Pro Asp
Lys Phe His Val
Lys Phe Val His
Lys Gly Tyr Tyr
Lys His Phe Val
Lys His Val Phe
Lys Val Phe His
Lys Val His Phe
Lys Tyr Gly Tyr
Lys Tyr Tyr Gly
Leu Asp Pro Trp
Leu Asp Trp Pro
Leu Phe His Asn
C25H35N7O6 (529.2648690000001)
Leu Phe Asn His
C25H35N7O6 (529.2648690000001)
Leu His Phe Asn
C25H35N7O6 (529.2648690000001)
Leu His Asn Phe
C25H35N7O6 (529.2648690000001)
Leu Asn Phe His
C25H35N7O6 (529.2648690000001)
Leu Asn His Phe
C25H35N7O6 (529.2648690000001)
Leu Asn Gln Arg
Leu Asn Arg Gln
Leu Pro Asp Trp
Leu Pro Trp Asp
Leu Gln Asn Arg
Leu Gln Arg Asn
Leu Arg Asn Gln
Leu Arg Gln Asn
Leu Trp Asp Pro
Leu Trp Pro Asp
Met His Arg Ser
Met His Ser Arg
Met Pro Pro Trp
C26H35N5O5S (529.2358780000001)
Met Pro Trp Pro
C26H35N5O5S (529.2358780000001)
Met Arg His Ser
Met Arg Ser His
Met Ser His Arg
Met Ser Arg His
Met Trp Pro Pro
C26H35N5O5S (529.2358780000001)
Asn Phe His Ile
C25H35N7O6 (529.2648690000001)
Asn Phe His Leu
C25H35N7O6 (529.2648690000001)
Asn Phe Ile His
C25H35N7O6 (529.2648690000001)
Asn Phe Leu His
C25H35N7O6 (529.2648690000001)
Asn His Phe Ile
C25H35N7O6 (529.2648690000001)
Asn His Phe Leu
C25H35N7O6 (529.2648690000001)
Asn His Ile Phe
C25H35N7O6 (529.2648690000001)
Asn His Leu Phe
C25H35N7O6 (529.2648690000001)
Asn Ile Phe His
C25H35N7O6 (529.2648690000001)
Asn Ile His Phe
C25H35N7O6 (529.2648690000001)
Asn Ile Gln Arg
Asn Ile Arg Gln
Asn Leu Phe His
C25H35N7O6 (529.2648690000001)
Asn Leu His Phe
C25H35N7O6 (529.2648690000001)
Asn Leu Gln Arg
Asn Leu Arg Gln
Asn Gln Ile Arg
Asn Gln Leu Arg
Asn Gln Arg Ile
Asn Gln Arg Leu
Asn Arg Ile Gln
Asn Arg Leu Gln
Asn Arg Gln Ile
Asn Arg Gln Leu
Pro Asp Ile Trp
Pro Asp Leu Trp
Pro Asp Trp Ile
Pro Asp Trp Leu
Pro Glu Glu Arg
C21H35N7O9 (529.2496140000001)
Pro Glu Arg Glu
C21H35N7O9 (529.2496140000001)
Pro Glu Val Trp
Pro Glu Trp Val
Pro Ile Asp Trp
Pro Ile Trp Asp
Pro Leu Asp Trp
Pro Leu Trp Asp
Pro Met Pro Trp
C26H35N5O5S (529.2358780000001)
Pro Met Trp Pro
C26H35N5O5S (529.2358780000001)
Pro Pro Met Trp
C26H35N5O5S (529.2358780000001)
Pro Pro Trp Met
C26H35N5O5S (529.2358780000001)
Pro Arg Glu Glu
C21H35N7O9 (529.2496140000001)
Pro Val Glu Trp
Pro Val Trp Glu
Pro Trp Asp Ile
Pro Trp Asp Leu
Pro Trp Glu Val
Pro Trp Ile Asp
Pro Trp Leu Asp
Pro Trp Met Pro
C26H35N5O5S (529.2358780000001)
Pro Trp Pro Met
C26H35N5O5S (529.2358780000001)
Pro Trp Val Glu
Gln Ala Arg Arg
C20H39N11O6 (529.3084633999999)
Gln Phe His Val
C25H35N7O6 (529.2648690000001)
Gln Phe Val His
C25H35N7O6 (529.2648690000001)
Gln His Phe Val
C25H35N7O6 (529.2648690000001)
Gln His Val Phe
C25H35N7O6 (529.2648690000001)
Gln Ile Asn Arg
Gln Ile Arg Asn
Gln Leu Asn Arg
Gln Leu Arg Asn
Gln Asn Ile Arg
Gln Asn Leu Arg
Gln Asn Arg Ile
Gln Asn Arg Leu
Gln Gln Arg Val
Gln Gln Val Arg
Gln Arg Ala Arg
C20H39N11O6 (529.3084633999999)
Gln Arg Ile Asn
Gln Arg Leu Asn
Gln Arg Asn Ile
Gln Arg Asn Leu
Gln Arg Gln Val
Gln Arg Arg Ala
C20H39N11O6 (529.3084633999999)
Gln Arg Val Gln
Gln Val Phe His
C25H35N7O6 (529.2648690000001)
Gln Val His Phe
C25H35N7O6 (529.2648690000001)
Gln Val Gln Arg
Gln Val Arg Gln
Arg Ala Phe His
Arg Ala His Phe
Arg Ala Gln Arg
C20H39N11O6 (529.3084633999999)
Arg Ala Arg Gln
C20H39N11O6 (529.3084633999999)
Arg Glu Glu Pro
C21H35N7O9 (529.2496140000001)
Arg Glu Pro Glu
C21H35N7O9 (529.2496140000001)
Arg Phe Ala His
Arg Phe His Ala
Arg His Ala Phe
Arg His Phe Ala
Arg His Met Ser
Arg His Ser Met
Arg Ile Asn Gln
Arg Ile Gln Asn
Arg Leu Asn Gln
Arg Leu Gln Asn
Arg Met His Ser
Arg Met Ser His
Arg Asn Ile Gln
Arg Asn Leu Gln
Arg Asn Gln Ile
Arg Asn Gln Leu
Arg Pro Glu Glu
C21H35N7O9 (529.2496140000001)
Arg Gln Ala Arg
C20H39N11O6 (529.3084633999999)
Arg Gln Ile Asn
Arg Gln Leu Asn
Arg Gln Asn Ile
Arg Gln Asn Leu
Arg Gln Gln Val
Arg Gln Arg Ala
C20H39N11O6 (529.3084633999999)
Arg Gln Val Gln
Arg Arg Ala Gln
C20H39N11O6 (529.3084633999999)
Arg Arg Gln Ala
C20H39N11O6 (529.3084633999999)
Arg Ser His Met
Arg Ser Met His
Arg Val Gln Gln
Ser His Met Arg
Ser His Arg Met
Ser Met His Arg
Ser Met Arg His
Ser Arg His Met
Ser Arg Met His
Val Glu Pro Trp
Val Glu Trp Pro
Val Phe His Lys
Val Phe His Gln
C25H35N7O6 (529.2648690000001)
Val Phe Lys His
Val Phe Gln His
C25H35N7O6 (529.2648690000001)
Val His Phe Lys
Val His Phe Gln
C25H35N7O6 (529.2648690000001)
Val His Lys Phe
Val His Gln Phe
C25H35N7O6 (529.2648690000001)
Val Lys Phe His
Val Lys His Phe
Val Pro Glu Trp
Val Pro Trp Glu
Val Gln Phe His
C25H35N7O6 (529.2648690000001)
Val Gln His Phe
C25H35N7O6 (529.2648690000001)
Val Gln Gln Arg
Val Gln Arg Gln
Val Arg Gln Gln
Val Trp Glu Pro
Val Trp Pro Glu
Trp Asp Ile Pro
Trp Asp Leu Pro
Trp Asp Pro Ile
Trp Asp Pro Leu
Trp Glu Pro Val
Trp Glu Val Pro
Trp Ile Asp Pro
Trp Ile Pro Asp
Trp Leu Asp Pro
Trp Leu Pro Asp
Trp Met Pro Pro
C26H35N5O5S (529.2358780000001)
Trp Pro Asp Ile
Trp Pro Asp Leu
Trp Pro Glu Val
Trp Pro Ile Asp
Trp Pro Leu Asp
Trp Pro Met Pro
C26H35N5O5S (529.2358780000001)
Trp Pro Pro Met
C26H35N5O5S (529.2358780000001)
Trp Pro Val Glu
Trp Val Glu Pro
Trp Val Pro Glu
Tyr Gly Lys Tyr
Tyr Gly Tyr Lys
Tyr Lys Gly Tyr
Tyr Lys Tyr Gly
Tyr Tyr Gly Lys
Tyr Tyr Lys Gly
N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfoxy)cholan-24-yl]-Glycine
N-[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy)cholan-24-yl]-Glycine
Glycine, N-[(3a,5b,7b)-3-hydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]
Glycine, N-[(3a,5b,7a)-3-hydroxy-24-oxo-7-(sulfooxy)cholan-24-yl]-
LysoPE(22:4/0:0)
Malformin
C23H39N5O5S2 (529.2392484000001)
Malformin-B4
C23H39N5O5S2 (529.2392484000001)
Glycochenodeoxycholate 7-sulfate
1-propanesulfonic acid 3,3-(hexadecylimino) bisdisodium salt
C22H45NNa2O6S2 (529.2483550000001)
Haloperidol decanoate
C31H41ClFNO3 (529.2758838000001)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist
(E)-4-[[3-(acetylhydroxyamino)propyl]-amino]-2-hydroxy-2-[2-[3-[hydroxy(1-oxo-2-decenyl)amino]propyl]amino]-2-oxoethyl]-4-oxobutanoic acid
(2R)-2-Acetyl-1-[(2S)-2-[acetyl-[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-aminohexanoyl]pyrrolidine-2-carboxylic acid
(5Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine
N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
N-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
N-[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
N-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
N-[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
1-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea
1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea
2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea
1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea
1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea
2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea
1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea
3-(2,5-difluorophenyl)-1-[[(2S,3R)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea
1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methyl-2-naphthalenesulfonamide
C26H35N5O5S (529.2358780000001)
3-(2,5-difluorophenyl)-1-[[(2R,3S)-8-[3-(dimethylamino)prop-1-ynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea
1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea
1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1R)-1-phenylethyl]urea
1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-[(1S)-1-phenylethyl]urea
2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]-2-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] hexanoate
[3-acetyloxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] butanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] acetate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
sulfoglycochenodeoxycholic acid
A steroid sulfate that is the 3-O-sulfo derivative of glycochenodeoxycholic acid.
PE(22:4/0:0)
A lysophosphatidylethanolamine 22:4 in which the acyl group is located at position 1.
N(6)-acetylkanamycin B(4+)
A quadruply-charged ammonium ion arising from protonation of the four free amino groups of N(6)-acetylkanamycin; major species at pH 7.3.
PE(22:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PC(18:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PE(21:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LdMePE(20:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
MePC(18:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
MePC(17:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PC(19:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Glycochenodeoxycholic acid 3-sulfate
-
(1s,2r,3ar)-9b-hydroxy-1-methoxy-n3a-[(4s)-1-methoxy-7-methyl-1,5-dioxooct-6-en-4-yl]-n2,3-dimethyl-4-oxo-1h,2h,5h-benzo[e]indole-2,3a-dicarboximidic acid
C27H35N3O8 (529.2424030000001)
(2s,3s,6r)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl (3r)-3-hydroxy-3-(4-methylpentyl)butanedioate
(2s)-n-[(1s)-2-hydroxy-1-{[(1s)-1-{[(2s)-1-methoxy-1-oxobutan-2-yl]-c-hydroxycarbonimidoyl}-2-phenylethyl]-c-hydroxycarbonimidoyl}ethyl]-2-(1h-pyrrol-2-ylformamido)butanimidic acid
(2r,3s,6s)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl (3s)-3-hydroxy-3-(4-methylpentyl)butanedioate
2-{4,6'-dihydroxy-2',5',5',8'a-tetramethyl-6-oxo-3,3',4',4'a,6',7',8,8'-octahydro-2'h-spiro[furo[2,3-e]isoindole-2,1'-naphthalen]-7-yl}-5-methoxy-5-oxopentanoic acid
10-isopropyl-4,7-bis(sec-butyl)-15,16-dithia-2,5,8,11,19-pentaazabicyclo[11.4.2]nonadeca-2,5,8,11,18-pentaene-3,6,9,12,18-pentol
C23H39N5O5S2 (529.2392484000001)